Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP505, has been granted by US FDA

1.Date of occurrence of the event: 2023/01/14 2.New drug name or code: Bispecific Antibody, AP505 3.Indication: Bispecific antibody AP505 is a novel cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). It suppresses tumor growth through dual-blockade of PD-L1 and VEGF signaling pathways, and therefore, avoids immune escape of tumor cells and inhibits […]